As biotech startups sing the blues over 2012 VC deals, others hum a new tune
This article was originally published in Scrip
Venture capital investment in US biotechnology companies ended 2012 on a low note with just $4.1 billion invested in the industry versus the $4.9 billion in 2011. The decline was even more dramatic for startups, since first-time investments in early-stage firms were cut by more than half from $922.3 million to $438.3 million last year.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.